Fig. 5: PGM2L1 promotes the glycolysis and progression of TNBC cells under hypoxia. | Cell Death & Disease

Fig. 5: PGM2L1 promotes the glycolysis and progression of TNBC cells under hypoxia.

From: Cancer-associated fibroblasts secrete CSF3 to promote TNBC progression via enhancing PGM2L1-dependent glycolysis reprogramming

Fig. 5

Colorimetry assays to measure glycolysis level of MDA-MB-231 and MDA-MB-468 cells treated with hypoxic CAF-CM, including glucose (A), lactic acid (B), ATP (C), and G-6-P(D) (n = 3). E MTT assay to assess cellular proliferation with or without 2-DG (n = 4). MTT (F, n = 4) and EdU (G, n = 3) assays to evaluate the proliferative ability of TNBC cells treated with hypoxic CAF-CM following PGM2L1 silencing. H Transwell assay to assess the migration and invasion abilities of TNBC cells treated with hypoxic CAF-CM following PGM2L1 silencing (n = 3). Scale bars, 200 μm. I The EMT-makers were examined by western blot. J Fluorescent immunohistochemical staining of the expression of PGM2L1 and HIF-1α in TNBC tissues. Scale bars, 100 μm. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page